Cover Progress (NASDAQ: CGC) is a high-risk funding. The inventory has misplaced over 95% of its worth since its preliminary public providing. There was materials pleasure round marijuana shares and Cover Progress a couple of years in the past, however the firm has not lived as much as Wall Road’s maybe overzealous expectations. Now might be not the time to leap aboard.
At one level in 2019, a share of Cover Progress would have price over $560 (after adjusting for reverse splits). Right now, that very same share would fetch somewhat over a buck. It has, mainly, gone from being a Wall Road darling to being a penny inventory. Penny shares are high-risk investments which have a historical past of not understanding nicely for shareholders.
Will AI create the world’s first trillionaire? Our group simply launched a report on the one little-known firm, referred to as an “Indispensable Monopoly” offering the important know-how Nvidia and Intel each want. Proceed »
An organization does not discover itself in penny inventory land for no purpose. One materials drawback for Cover Progress is its historical past of shedding cash. In actual fact, after roughly a decade of being a public firm, it nonetheless hasn’t posted optimistic earnings. It is easy to grasp why buyers are bored with ready round.
In late 2025, in the meantime, the corporate introduced that it had recapitalized its steadiness sheet. That may be a optimistic occasion for the corporate, however not a great factor from an investor’s standpoint. Basically, the corporate’s monetary situation was so weak that it needed to lower offers with its bondholders. Notably, the corporate needed to problem warrants as an enticement for the bondholders to play alongside. If these warrants are exercised, they are going to result in shareholder dilution.
On the identical time, the corporate is shifting ahead with its acquisition of MTL Hashish. This, regardless of being a money-losing enterprise that simply needed to recapitalize its steadiness sheet. Shopping for MTL Hashish will strengthen Cover Progress’s place within the medical marijuana area. Nevertheless, it’s a cash-and-stock deal. So it places extra pressure on Cover Progress’s steadiness sheet and can end in shareholder dilution.
It’s fully doable that Cover Progress turns into a sustainably worthwhile enterprise. In actual fact, it will be simple sufficient to focus solely on the optimistic aspect of current company occasions. However additionally it is doable that this money-losing penny inventory is overextending itself. If that is the case, it might have hassle remaining a going concern. The danger-versus-reward profile for this marijuana inventory is tilted too far towards threat for all however probably the most aggressive buyers.